AstraZeneca is likely to run an additional global trial to assess the efficacy of the company’s Covid-19 vaccine using a lower dosage, the British drugmaker’s chief executive was quoted as saying amid questions over the results of a late-stage study.
After capturing record-breaking attendance at its spring Illuminate event, the Healthcare Businesswomen’s Association (HBA) brought together – virtually – the biggest Annual Conference crowd in the group’s history with more than 1,600 attendees from 15 countries representing 250 healthcare and life science companies.
Kate Cronin, Global CEO of Ogilvy Health, shares her views on a variety of healthcare industry topics in a Q&A with PharmaLive.
Urovant Sciences and Genmab reported disappointing clinical trial announcements.
Purdue Pharma LP pleaded guilty to criminal charges over the handling of the company’s addictive prescription painkiller OxyContin, capping a deal with federal prosecutors to resolve an investigation into the drugmaker’s role in the U.S. opioid crisis.
To support the long-term goals of Novartis, the Swiss pharma giant is initiating a share-buyback program of up to $2.5 billion that is expected to be carried out over the next few months.
Two months after stepping down from the role of chief executive officer of Legend Biotech, Fangliang “Frank” Zhang was arrested for smuggling genetic resources from the People’s Republic of China.
Clene Nanomedicine is trying to set a new “gold standard” in neurodegenerative diseases through the development of a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals.
Players in the National Football League must wear masks on the sidelines unless they have their helmet on and are preparing to enter the game, the league said as the NFL unveiled an enhanced set of Covid-19 protocols.
The U.S. Food and Drug Administration approved Eiger BioPharmaceuticals’ Zokinvy for Hutchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies.